Evidence map›Paper›PMID 29657678›Full record

ArticleOman medical journal2018

Safety of Sodium-Glucose Cotransporter 2 Inhibitors (SGLT2-I) During the Month of Ramadan in Muslim Patients with Type 2 Diabetes.

Alaaeldin Bashier, Azza Abdulaziz Khalifa, Elamin Ibrahim Abdelgadir, Maryam Ahmad Al Saeed, Amina Adil Al Qaysi, Murad Burhan Ali Bayati, Budoor Alemadi, Fawzi Bachet, Fatheya Alawadi, Mohammed Hassanein

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oman medical journal, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed, 2 pooled it
2.6field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 2 syntheses or guidelines pooled it, 48 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Review
  5. Article
  6. Article
  7. Observational
  8. Article
  9. Article
  10. Review
  11. Safety and tolerability of Empagliflozin use during the holy month of Ramadan by fasting patients with type 2 diabetes: A prospective cohort study.Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2023
    Article
  12. Observational
  13. Review
  14. Review
  15. Review
  16. Article
  17. Article
  18. Diabetes management during Ramadan amid Covid-19 pandemic.Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences · 2020
    Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Alaaeldin BashierEndocrine Department, Dubai Hospital, Dubai, UAE.
Azza Abdulaziz KhalifaEndocrine Department, Dubai Hospital, Dubai, UAE.
Elamin Ibrahim AbdelgadirEndocrine Department, Dubai Hospital, Dubai, UAE.
Maryam Ahmad Al SaeedEndocrine Department, Dubai Hospital, Dubai, UAE.
Amina Adil Al QaysiInternal Medicine Residency Program, Dubai Hospital, Dubai, UAE.
Murad Burhan Ali BayatiInternal Medicine Residency Program, Dubai Hospital, Dubai, UAE.
Budoor AlemadiEndocrine Department, Dubai Hospital, Dubai, UAE.
Fawzi BachetEndocrine Department, Dubai Hospital, Dubai, UAE.
Fatheya AlawadiEndocrine Department, Dubai Hospital, Dubai, UAE.
Mohammed HassaneinEndocrine Department, Dubai Hospital, Dubai, UAE.
Dubai Hospital · AE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesSodium-glucose cotransporter 2 inhibitors (SGLT2-I) are a new class of antidiabetic drugs that might increase the risk of dehydration and hypoglycemia, particularly during the month of Ramadan in which Muslims abstain from eating and drinking for 14-16 hours daily. We aimed to provide real-life evidence about the safety of SGLT2-I during Ramadan.

methodsAll patients over the age of 18 years on SGLT2-I before Ramadan 2016 who would be fasting during Ramadan were included. Demographic data, detailed medical history including comorbidities and medication profile, and laboratory results were collected before and after Ramadan. We also conducted a phone interview to evaluate the frequency and severity of hypoglycemia and dehydration.

resultsOf the total of 417 patients, 113 (27.0%) experienced hypoglycemic events, and 93 of these (82.3%) checked their blood glucose using a glucometer. Confirmed hypoglycemia (< 70 mg/dL) was observed in 78 (83.8%). The hypoglycemic events were significantly more frequent in the SGLT2-I plus insulin-treated group than in those treated with SGLT2-I plus oral hypoglycemic agents group (

conclusionsThe use of insulin in combination with SGLT2-I increases the risk of hypoglycemia during Ramadan. Hypoglycemic events were mild and did not require hospital admission. However, careful monitoring during prolonged fasting is warranted. No significant harmful effects on renal function result from treatment with SGLT2-I during Ramadan.

Indexed as

Diabetes Mellitus, Type 2FastingSafetySGLT2

Identifiers

PMID29657678
PMCPMC5889836
OpenAlexW2796876561

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.